Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,121 public trials 2,033 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

NCT03458260

Conditions
Aggressive Non-Hodgkin Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +13 more
Locations
  • AZ Sint Jan Bruges, Belgium
  • Institut Jules Bordet - Centre des tumeurs de l'ULB Brussels, Belgium
  • Centre Hospitalier de Jolimont Haine-Saint-Paul, Belgium
  • CH d'Avignon Avignon, France
View all 22 locations
View Trial Details
Completed

A Study of Ninlaro in Real World Clinical Practice in China

NCT04328662

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Anhui Cancer Hospital Hefei, Anhui, China
  • Beijing Chao-yang Hospital,Capital Medical University Beijing, Beijing Municipality, China
  • Peking University First Hospital Beijing, Beijing Municipality, China
  • Beijing Jishuitan Hospital Beijing, Beijing Municipality, China
View all 28 locations
View Trial Details
Completed

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

NCT03601078

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Mayo Clinic in Arizona - Scottsdale Scottsdale, Arizona, United States
  • University Of California San Francisco Medical Center San Francisco, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Emory University School of Medicine Atlanta, Georgia, United States
View all 25 locations
View Trial Details
Completed

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

NCT04285567

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia (CLL), Disease Attributes, +14 more
Locations
  • Medical Center of Aurora Aurora, Colorado, United States
  • American Oncology Partners of Maryland, PA Bethesda, Maryland, United States
  • University of Tennessee Medical Center;Office of Clinical Trials Knoxville, Tennessee, United States
  • Oncology & Hematology Associates of Southwest Virginia, Inc._Goldschmidt Roanoke, Virginia, United States
View all 40 locations
View Trial Details
Completed

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

NCT03939026

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Stanford University Stanford, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View Trial Details
Completed

Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

NCT01919086

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Hartford Healthcare Cancer Institute @ Hartford Hospital Hartford, Connecticut, United States
  • Memorial Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States
View Trial Details

Related conditions